Amifostine protects against cisplatin-induced ototoxicity in children with average-risk medulloblastoma.
about
Medical interventions for the prevention of platinum-induced hearing loss in children with cancerMedical interventions for the prevention of platinum-induced hearing loss in children with cancerMedical interventions for the prevention of platinum-induced hearing loss in children with cancerPlatinum-induced ototoxicity in children: a consensus review on mechanisms, predisposition, and protection, including a new International Society of Pediatric Oncology Boston ototoxicity scale.Cisplatin ototoxicity and protection: clinical and experimental studiesCisplatin and aminoglycoside antibiotics: hearing loss and its prevention.Carboplatin-associated ototoxicity in children with retinoblastoma.Evaluation of amifostine for protection against cisplatin-induced serious hearing loss in children treated for average-risk or high-risk medulloblastoma.Clinical pharmacokinetics of amifostine and WR1065 in pediatric patients with medulloblastoma.Pathophysiology of Chemotherapy-Induced Peripheral Neuropathy.Ototoxicity evaluation in medulloblastoma patients treated with involved field boost using intensity-modulated radiation therapy (IMRT): a retrospective reviewTranstympanic administration of short interfering (si)RNA for the NOX3 isoform of NADPH oxidase protects against cisplatin-induced hearing loss in the rat.Relevance of historical therapeutic approaches to the contemporary treatment of pediatric solid tumors.N-acetylcysteine chemoprotection without decreased cisplatin antitumor efficacy in pediatric tumor models.Common variants in ACYP2 influence susceptibility to cisplatin-induced hearing lossConcordance between the chang and the International Society of Pediatric Oncology (SIOP) ototoxicity grading scales in patients treated with cisplatin for medulloblastoma.Cumulative cisplatin dose is not associated with event-free or overall survival in children with newly diagnosed average-risk medulloblastoma treated with cisplatin based adjuvant chemotherapy: report from the Children's Oncology Group.New Insights into Potential Prevention and Management Options for Chemotherapy-Induced Peripheral Neuropathy.SOD2 genetic variant associated with treatment-related ototoxicity in cisplatin-treated pediatric medulloblastomaGlutathione S-transferase P1 single nucleotide polymorphism predicts permanent ototoxicity in children with medulloblastoma.Systemic cancer therapy: achievements and challenges that lie aheadGenetic variants associated with cisplatin-induced ototoxicity.The role of inherited TPMT and COMT genetic variation in cisplatin-induced ototoxicity in children with cancer.Pharmacotherapy of neuroblastoma.Ten challenges in the management of neuroblastoma.Ototoxicity (cochleotoxicity) classifications: A review.The role of germline variants in chemotherapy outcome in brain tumors: a systematic review of pharmacogenetic studies.Medical interventions for the prevention of platinum-induced hearing loss in children with cancer.Effects of sodium thiosulfate versus observation on development of cisplatin-induced hearing loss in children with cancer (ACCL0431): a multicentre, randomised, controlled, open-label, phase 3 trial.Role of TPMT and COMT genetic variation in cisplatin-induced ototoxicity.Mechanisms of Cisplatin-Induced Ototoxicity and Otoprotection.Acquired sensorineural hearing loss in children: current research and therapeutic perspectives.Audiological monitoring in Swiss childhood cancer patients.DNA methylation of a novel PAK4 locus influences ototoxicity susceptibility following cisplatin and radiation therapy for pediatric embryonal tumors.Ototoxicity: A Challenge in Diagnosis and Treatment.CDK2 inhibitors as candidate therapeutics for cisplatin- and noise-induced hearing loss.Early cisplatin induced ototoxicity profile may predict the need for hearing support in children with medulloblastoma.Hearing loss among survivors of childhood brain tumors treated with an irradiation-sparing approach.Economic impact of a genetic test for cisplatin-induced ototoxicity.Anatomical and physiological basis for the allometric scaling of cisplatin clearance in dogs.
P2860
Q24194929-F4F1A9C0-2F6E-4063-A36C-8D9269D06668Q24197812-73C278D3-4450-4DCA-BCBF-74195A292909Q24236069-A52D8324-FB96-4DBF-B16E-D96904BE243EQ24615296-54DE54E5-2C2A-4C87-A13B-F62DF756B931Q24628775-4FF1B385-07B2-48A4-9C38-503253A4809CQ30447637-2F8B16A5-C6B4-4D36-B0D2-DA6BD0678BFAQ30513911-83458063-57D0-43D4-BD9B-6BE3318013F5Q30578179-23559463-F2A8-4B12-93EF-73E3193616E8Q33638876-14E030A1-4FB1-4666-BDD1-E29090E954AEQ33744706-CD77FDA6-9144-4D73-8001-F609FDC85B29Q33985538-389606CA-7DE1-4BD2-9E34-2EEB1C4F2C3FQ34110153-0D8C4765-77A1-4F36-B1F7-7019147EEC94Q34589401-D9A74677-8513-4C50-A027-6BBE239062C3Q35071886-1E97C43E-EF92-442C-8460-7C604366345BQ35172741-0CDD9CEA-AEF8-4E27-8396-B42094094BD1Q35211949-3EC977BA-C508-49D9-8F4C-5CCFC144DF57Q36114760-E49A05FB-E0E8-49ED-BFB8-F5A090181881Q36226275-30341411-0777-429B-8ABE-E06DD212FCBDQ36358551-20AC6CC4-9951-4797-A1D3-1424E0CE4664Q36546317-FA53ABCA-24E6-41DE-B4A7-726B656B6A1AQ36821958-2041D042-1529-426D-89B0-7BBD3B53A5B9Q37293994-5A225BEE-9E74-447A-A076-C5E1471D88B3Q37444522-CB3B2602-C010-4154-9336-FDF83B492FEAQ37735199-E9F9BDB0-E064-4D87-A1DC-5ED132DBC6CAQ38029366-BBBA6A8B-EEA6-42FF-BEA7-C522D2F34B0AQ38653146-C0BDD34B-B853-48AB-9781-EFAF43BBB0A8Q38739253-6EF46535-B8AD-4E03-A134-8AC5C8132BE7Q38964704-AFAE369C-4D5D-4A80-9496-71BF3AFE47D9Q40443233-8CC68E13-FC0D-41CC-B279-A5548134C83CQ45354484-A94E90ED-97FF-43B4-8874-EE7A60893234Q46256727-110110AF-4415-414C-847B-721324B57E73Q47554578-8B10320B-42CE-4F47-A388-A751CA6B8C14Q47577823-4A83B123-9F18-4607-9E1D-809727688FE4Q48659411-8C5F7F6A-4DC4-4124-885E-BAA549427E4BQ50300972-33154270-657B-4450-83D6-24A4D2FA73D9Q50420474-6FE45905-071E-436F-B554-7E546A484184Q50428964-50E9755D-7826-404E-8F03-FEB2F36447CCQ50433278-824A573A-7E49-47E5-9FA1-D97C46A1F926Q50434327-65A41396-61D2-4EEF-AFE2-66AB3E51BF13Q50798269-846B405E-F068-47EE-83D9-49F3617B44D3
P2860
Amifostine protects against cisplatin-induced ototoxicity in children with average-risk medulloblastoma.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
2008年论文
@zh
2008年论文
@zh-cn
name
Amifostine protects against ci ...... average-risk medulloblastoma.
@en
type
label
Amifostine protects against ci ...... average-risk medulloblastoma.
@en
prefLabel
Amifostine protects against ci ...... average-risk medulloblastoma.
@en
P2093
P2860
P50
P356
P1476
Amifostine protects against ci ...... average-risk medulloblastoma.
@en
P2093
Alberto Broniscer
Amar Gajjar
Brannon Morris
Clinton F Stewart
Dana Wallace
David Ashley
Gregory A Hale
James M Boyett
Kimberly A Kasow
Larry E Kun
P2860
P304
P356
10.1200/JCO.2007.14.3974
P407
P577
2008-08-01T00:00:00Z